Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Genetic and biochemical characterization of OXA-1054, a carbapenem-hydrolyzing class D β-lactamase conferring broad-spectrum β-lactam resistance in Pseudomonas aeruginosa

  • González-Pinto, Lucía
  • Monge-Olivares, Laura
  • Pérez-Rodríguez, Gloria
  • Aja-Macaya, Pablo
  • Sánchez-Peña, Lucía
  • Gomis-Font, María Antonia
  • Rodríguez-Pallares, Salud
  • Blanco Martín, Tania
  • López-Cerero, Lorena
  • Beceiro Casas, Alejandro
  • Bogaerts, Pierre
  • Oliver, Antonio
  • Bou, Germán
  • Arca-Suárez, Jorge
[Abstract] We aimed to characterize OXA-1054, a novel carbapenem-hydrolyzing class D β-lactamase (CHDL) detected in a multidrug-resistant Pseudomonas aeruginosa clinical isolate. Antimicrobial susceptibility was determined by broth microdilution, and carbapenemase activity was confirmed by hydrolysis assays. Whole-genome sequencing via Illumina and PacBio platforms enabled comprehensive analysis of the resistome and plasmid architecture. The blaOXA-1054 gene was cloned in parallel with blaOXA-48 and blaOXA-198 into the pUCP24 plasmid. β-Lactamases were produced in P. aeruginosa PAO1 for comparative evaluation of the phenotypic impact of each. OXA-48, OXA-198, and OXA-1054 β-lactamases were purified and further subjected to steady-state kinetic analysis, and 50% inhibitory activity of β-lactamase inhibitors was determined. The clinical P. aeruginosa isolate ARGA00461 showed resistance to carbapenems and most β-lactam/β-lactamase inhibitor combinations and tested positive in carbapenem hydrolysis assays. Genomic analysis revealed that the P. aeruginosa isolate ARGA00461 carried a gene coding for a previously uncharacterized CHDL, designated OXA-1054, which is closely related to the OXA-372 enzyme of environmental origin. The blaOXA-1054 gene was located in a small (≈5 kbp) non-conjugative plasmid coexisting with a conjugative IncP plasmid, which likely facilitated its mobilization. Production of OXA-1054 in P. aeruginosa PAO1 conferred a broader spectrum of β-lactam resistance than other CHDLs. Enzyme kinetics confirmed carbapenem hydrolysis with catalytic efficiency comparable to OXA-48 and revealed higher affinity for cefepime compared to OXA-48 and OXA-198. Among the inhibitors tested, only avibactam demonstrated relevant inhibitory activity. OXA-1054 mediates broad-spectrum β-lactam resistance in P. aeruginosa, including carbapenems and β-lactam/β-lactamase inhibitor combinations., This study was supported by Instituto de Salud Carlos III (ISCIII) through projects PI21/00704, PI22/01212, PI24/00010, PI24/00920, and PI25/00116 and co-funded by the European Union. The research was also funded by Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC, CB21/13/00055 and CB21/13/00099). Funding was also provided by Axencia Galega de Innovación (GAIN), Consellería de Innovación and Consellería de Economía, Emprego e Industria, Xunta de Galicia (IN607D 2021/12 to A.B., IN607A 2024/09 to G.B., and IN607D 2024/08 to J.A.-S.). L.G.-P. was financially supported by the ISCIII PFIS program (FI23/00074). G.P.-R. was supported by PI22/01212 and GAIN-Xunta de Galicia (IN606A 2025/020). L.S.-P. was financially supported by GAIN-Xunta de Galicia (IN606A 2024/022). M.A.G.-F. was financially supported by the ISCIII PFIS program (FI22/00039). S.R.-P. was financially supported by the ISCIII Río Hortega program (CM23/00104). T.B.-M. was financially supported by the ISCIII Juan Rodés program (JR25/00031). J.A.-S. was financially supported by the ISCIII Juan Rodés program (JR21/00026).
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Comparative activity of ceftibuten combinations with avibactam, ledaborbactam, and xeruborbactam against recombinant β-lactamase-producing Escherichia coli and contemporary WGS-characterized strains of carbapenemase-producing Enterobacterales

  • Sánchez-Peña, Lucía
  • Rodríguez-Pallares, Salud
  • Blanco Martín, Tania
  • Pérez-Rodríguez, Gloria
  • Aja-Macaya, Pablo
  • González-Pinto, Lucía
  • López-Hernández, Inmaculada
  • Aracil, Belén
  • Beceiro Casas, Alejandro
  • Bou, Germán
  • Arca-Suárez, Jorge
Comparative study, [Abstract] We evaluated the activity of ceftibuten combinations with avibactam, ledaborbactam, and xeruborbactam against isogenic Escherichia coli and clinical Enterobacterales isolates producing broad-spectrum β-lactamases. Avibactam and ledaborbactam enhanced ceftibuten activity against transformants producing serine-β-lactamases. Ceftibuten/xeruborbactam was also active against VIM and some IMP producers. All combinations were active against OXA-48- and KPC-producing clinical isolates. Ceftibuten/xeruborbactam also retained activity against VIM-producing clinical strains. Susceptibility rates for MBL producers varied, depending on the CLSI or EUCAST breakpoints applied., This study was supported by the Instituto de Salud Carlos III (ISCIII) through projects PI21/00704, PI22/01212, PI23/00851, PI24/00920, and PI25/00116 co-funded by the European Union. The research was also funded by Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CB21/13/00055). Funding was also provided by Axencia Galega de Innovación (GAIN), Consellería de Innovación, Consellería de Economía, Emprego e Industria, and Xunta de Galicia (IN607D 2021/12 to A.B., IN607A 2024/09 to G.B., and IN607D 2024/08 to J.A.-S.). L.S.-P. was financially supported by GAIN-Xunta de Galicia (IN606A 2024/022). S.R.-P. was financially supported by the ISCIII Río Hortega program (CM23/00104). T.B.-M. was financially supported by the ISCIII Río Hortega program (CM23/00095). G.P.-R. was supported by PI22/01212 and GAIN-Xunta de Galicia (IN606A 2025/020). L.G.-P. was financially supported by the ISCIII PFIS program (FI23/00074). J.A.-S. was financially supported by the ISCIII Juan Rodés program (JR21/00026).